While some emerging data suggest potential benefits for muscle quality and metabolic function, systematic reviews show that GLP-1 therapy is still associated with measurable reductions in lean mass, particularly in individuals with diabetes or low baseline muscle reserves [27]. Here, GLP1R is linked to diabetes mellitus.